

CORRECTION

Correction: FKBP10 ablation promotes breast cancer chemosensitivity via targeting autophagy and the AKT/CREB axis

Long Cheng¹, Xiang Zhu¹, Zihe Xing¹, Xiaoning Li¹, Wuqin Xu^{2,*}

¹Clinical Laboratory, The First Affiliated Hospital of Wannan Medical College, 241001 Wuhu, Anhui, China

²Department of Pathology, The First Affiliated Hospital of Wannan Medical College, 241001 Wuhu, Anhui, China

***Correspondence**

xuwuqin06@126.com (Wuqin Xu)

The authors wish to issue the following correction to the published article [1]:

Two citations in the Introduction and Discussion sections were not optimally matched to the supported statements. These have been replaced with more appropriate and directly relevant references. These changes do not affect the results, their interpretation, or the overall conclusions of the study.

Revised References:

[5] Liu Q, Hou L, Zhao Y, Yang H, Mo Z, Yu F. Comparative efficacy & safety of buparlisib plus fulvestrant, fulvestrant plus dalpiciclib, and ribociclib plus letrozole for postmenopausal, hormone receptor-positive, and HER2-negative breast cancer. *Clinics*. 2023; 78: 100291.

[23] Li Y, Zhang C, Chen J, Tu G, Tang L. FKBP10 expression and TP53 mutation predict prognosis and chemotherapy response in triple-negative breast cancer. *Discover Oncology*. 2025; 16: 1409.

The authors sincerely apologize for any inconvenience or confusion this may have caused.

REFERENCES

- [1] Cheng L, Zhu X, Xing ZH, Li XN, Xu WQ. FKBP10 ablation promotes breast cancer chemosensitivity via targeting autophagy and the AKT/CREB axis. *European Journal of Gynaecological Oncology*. 2025; 46: 60–69.